The mitochondrial p53 pathway

Biochimica et Biophysica Acta - Bioenergetics

Volumn 1787, Issue 5, 2009, Pages 414-420

  Vaseva, Angelina V ^a   Moll, Ute M ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Apoptosis; Bcl 2 family; Ischemia; Mitochondria; p53; Pathophysiology; Radiosensitivity; Transcription

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; AD5 LP53WTM PROTEIN; AD5 WTP53 PROTEIN; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BCL2 RELATED PROTEIN A1; HYBRID PROTEIN; LP53WT FUSION PROTEIN; NUTLIN; P53 BCL XL FUSION PROTEIN; P53 BCL2 FUSION PROTEIN; PRIMA MOLECULE; PROTEIN BCL 2; PROTEIN P53; RITA MOLECULE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER GENE THERAPY; CELL AGING; CELL CYCLE ARREST; CLINICAL TRIAL; DNA REPAIR; GENETIC STABILITY; HEAD AND NECK CARCINOMA; HUMAN; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW;

APOPTOSIS; BRAIN ISCHEMIA; CELL DEATH; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, TUMOR SUPPRESSOR; HUMANS; KIDNEY DISEASES; MITOCHONDRIA; NEOPLASMS; PROTEIN TRANSPORT; REPERFUSION INJURY; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67349086630     PISSN: 00052728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbabio.2008.10.005     Document Type: Review

References (61)

1. Laptenko O., and Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13 (2006) 951-961
2. Caelles C., Helmberg A., and Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370 (1994) 220-223
3. Haupt Y., Rowan S., Shaulian E., Vousden K.H., and Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9 (1995) 2170-2183
4. Ding H.F., McGill G., Rowan S., Schmaltz C., Shimamura A., and Fisher D.E. Oncogene-dependent regulation of caspase activation by p53 protein in a cell-free system. J. Biol. Chem. 273 (1998) 28378-28383
5. Gottlieb E., and Oren M. p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J. 17 (1998) 3587-3596
6. Kroemer G., Galluzzi L., and Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87 (2007) 99-163
7. Marchenko N.D., Zaika A., and Moll U.M. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 275 (2000) 16202-16212
8. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., and Moll U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11 (2003) 577-590
9. Arima Y., Nitta M., Kuninaka S., Zhang D., Fujiwara T., Taya Y., Nakao M., and Saya H. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J. Biol. Chem. 280 (2005) 19166-19176
10. Moll U.M., Marchenko N., and Zhang X.K. p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 25 (2006) 4725-4743
11. Sansome C., Zaika A., Marchenko N.D., and Moll U.M. Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. FEBS Lett. 488 (2001) 110-115
12. Tomita Y., Marchenko N., Erster S., Nemajerova A., Dehner A., Klein C., Pan H., Kessler H., Pancoska P., and Moll U.M. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem. 281 (2006) 8600-8606
13. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., and Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
14. Petros A.M., Gunasekera A., Xu N., Olejniczak E.T., and Fesik S.W. Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett. 559 (2004) 171-174
15. B. Sot, S.M. Freund, A.R. Fersht, Comparative biophysical characterization of p53 with the pro-apoptotic Bak and the anti-apoptotic BCL-XL, J. Biol. Chem. (2007) Oct 5;282(40):29193-200.
16. Leu J.I., Dumont P., Hafey M., Murphy M.E., and George D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6 (2004) 443-450
17. Pietsch E.C., Perchiniak E., Canutescu A.A., Wang G., Dunbrack R.L., and Murphy M.E. Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. J. Biol. Chem. 283 (2008) 21294-21304
18. Chipuk J.E., Bouchier-Hayes L., Kuwana T., Newmeyer D.D., and Green D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309 (2005) 1732-1735
19. S. Wolff, S. Erster, G. Palacios, U.M. Moll, p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity, Cell Research 2008 Jul;18(7):733-44.
20. Heyne K., Schmitt K., Mueller D., Armbruester V., Mestres P., and Roemer K. Resistance of mitochondrial p53 to dominant inhibition. Mol. Cancer 7 (2008) 54
21. Nemajerova A., Erster S., and Moll U.M. The post-translational phosphorylation and acetylation modification profile is not the determining factor in targeting endogenous stress-induced p53 to mitochondria. Cell Death Differ. 12 (2005) 197-200
22. Haglund K., Di Fiore P.P., and Dikic I. Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem. Sci. 28 (2003) 598-603
23. Sigismund S., Polo S., and Di Fiore P.P. Signaling through monoubiquitination. Curr. Top. Microbiol. Immunol. 286 (2004) 149-185
24. Thrower J.S., Hoffman L., Rechsteiner M., and Pickart C.M. Recognition of the polyubiquitin proteolytic signal. EMBO J. 19 (2000) 94-102
25. Marchenko N.D., Wolff S., Erster S., Becker K., and Moll U.M. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 26 (2007) 923-934
26. Marchenko N.D., and Moll U.M. The role of ubiquitination in the direct mitochondrial death program of p53. Cell Cycle 6 (2007) 1718-1723
27. Erster S., Mihara M., Kim R.H., Petrenko O., and Moll U.M. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol. Cell. Biol. 24 (2004) 6728-6741
28. Strom E., Sathe S., Komarov P.G., Chernova O.B., Pavlovska I., Shyshynova I., Bosykh D.A., Burdelya L.G., Macklis R.M., Skaliter R., Komarova E.A., and Gudkov A.V. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat. Chem. Biol. 2 (2006) 474-479
29. Endo H., Kamada H., Nito C., Nishi T., and Chan P.H. Mitochondrial translocation of p53 mediates release of cytochrome c and hippocampal CA1 neuronal death after transient global cerebral ischemia in rats. J. Neurosci. 26 (2006) 7974-7983
30. Endo H., Saito A., and Chan P.H. Mitochondrial translocation of p53 underlies the selective death of hippocampal CA1 neurons after global cerebral ischaemia. Biochem. Soc. Trans. 34 (2006) 1283-1286
31. Bonini P., Cicconi S., Cardinale A., Vitale C., Serafino A.L., Ciotti M.T., and Marlier L.N. Oxidative stress induces p53-mediated apoptosis in glia: p53 transcription-independent way to die. J. Neurosci. Res. 75 (2004) 83-95
32. Racay P., Tatarkova Z., Drgova A., Kaplan P., and Dobrota D. Effect of ischemic preconditioning on mitochondrial dysfunction and mitochondrial p53 translocation after transient global cerebral ischemia in rats. Neurochem. Res. 32 (2007) 1823-1832
33. Kelly K.J., Plotkin Z., Vulgamott S.L., and Dagher P.C. P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor. J. Am. Soc. Nephrol. 14 (2003) 128-138
34. Dagher P.C. Apoptosis in ischemic renal injury: roles of GTP depletion and p53. Kidney Int. 66 (2004) 506-509
35. McLaren B.K., Zhang P.L., and Herrera G.A. P53 protein is a reliable marker in identification of renal tubular injury. Appl. Immunohistochem. Mol. Morphol. 12 (2004) 225-229
36. Leu J.I., and George D.L. Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev. 21 (2007) 3095-3109
37. Martins C.P., Brown-Swigart L., and Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 (2006) 1323-1334
38. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007) 661-665
39. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., and Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
40. D.S. Lim, S.M. Bae, S.Y. Kwak, E.K. Park, J.K. Kim, S.J. Han, C.H. Oh, C.H. Lee,W.Y. Lee, W.S. Ahn, Adenovirus-mediated p53 treatment enhances photodynamic antitumor response, Hum. Gene Ther. (2006) Mar;17(3):347-52
41. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16 (2005) 1016-1027
42. Roth J.A. Adenovirus p53 gene therapy. Expert Opin. Biol. Ther. 6 (2006) 55-61
43. H. Sauthoff, T. Pipiya, S. Chen, S. Heitner, J. Cheng, Y.Q. Huang, W.N. Rom, J.G. Hay, Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2-and E1b-55kD-mediated degradation of p53, Cancer Gene Ther. (2006) Jul;13(7):686-95.
44. Yin S., and Goodrich D.W. Combination gene therapy with p53 and Thoc1/p84 is more effective than either single agent in an animal model of human pancreatic adenocarcinoma. Int. J. Oncol. 28 (2006) 781-785
45. Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev., Cancer 6 (2006) 107-116
46. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349 (2003) 2042-2054
47. Zeimet A.G., and Marth C. Why did p53 gene therapy fail in ovarian cancer?. Lancet Oncol. 4 (2003) 415-422
48. Palacios G., and Moll U.M. Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo. Oncogene 25 (2006) 6133-6139
49. Talos F., Petrenko O., Mena P., and Moll U.M. Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res. 65 (2005) 9971-9981
50. G. Palacios, H.C. Crawford, A. Vaseva, U.M. Moll, Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model, Cell Cycle 7 (2008) Aug 15;7(16):2584-90.
51. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33 (2003) 357-365
52. Achanta G., Sasaki R., Feng L., Carew J.S., Lu W., Pelicano H., Keating M.J., and Huang P. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J. 24 (2005) 3482-3492
53. de Souza-Pinto N.C., Harris C.C., and Bohr V.A. p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria. Oncogene 23 (2004) 6559-6568
54. Yoshida Y., Izumi H., Torigoe T., Ishiguchi H., Itoh H., Kang D., and Kohno K. p53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res. 63 (2003) 3729-3734
55. Falkenberg M., Gaspari M., Rantanen A., Trifunovic A., Larsson N.G., and Gustafsson C.M. Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA. Nat. Genet. 31 (2002) 289-294
56. Enriquez J.A., Fernandez-Silva P., Garrido-Perez N., Lopez-Perez M.J., Perez-Martos A., and Montoya J. Direct regulation of mitochondrial RNA synthesis by thyroid hormone. Mol. Cell. Biol. 19 (1999) 657-670
57. Casas F., Daury L., Grandemange S., Busson M., Seyer P., Hatier R., Carazo A., Cabello G., and Wrutniak-Cabello C. Endocrine regulation of mitochondrial activity: involvement of truncated RXRalpha and c-Erb Aalpha1 proteins. FASEB J. 17 (2003) 426-436
58. Ibrahim M.M., Razmara M., Nguyen D., Donahue R.J., Wubah J.A., and Knudsen T.B. Altered expression of mitochondrial 16S ribosomal RNA in p53-deficient mouse embryos revealed by differential display. Biochim. Biophys. Acta 1403 (1998) 254-264
59. Donahue R.J., Razmara M., Hoek J.B., and Knudsen T.B. Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function. FASEB J. 15 (2001) 635-644
60. Andrews R.M., Kubacka I., Chinnery P.F., Lightowlers R.N., Turnbull D.M., and Howell N. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat. Genet. 23 (1999) 147
61. Heyne K., Mannebach S., Wuertz E., Knaup K.X., Mahyar-Roemer M., and Roemer K. Identification of a putative p53 binding sequence within the human mitochondrial genome. FEBS Lett. 578 (2004) 198-202